SCHEMBL19512003

SCHEMBL19512003

CC(C)(C)c1ccc(Cc2ccc(NC(=O)Cc3ccc(Cl)c(Cl)c3)c(C(=O)O)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.52
▸ PKM P14618 2/20 0.52
▸ SERPINE1 P05121 1/20 0.49
▸ LTC4S Q16873 1/20 0.47
▸ NR1H4 Q96RI1 4/20 0.47
▸ TRPV1 Q8NER1 1/20 0.45
▸ NLRP3 Q96P20 1/20 0.44
▸ DVL1 O14640 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ KCNQ2 O43526 1/20 0.43
▸ PPARG P37231 2/20 0.42
▸ PPARA Q07869 1/20 0.42
▸ ANO1 Q5XXA6 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ CLK1 P49759 1/20 0.42
▸ KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19512033 0.89 SERPINE1 (0.49) KDM4EPKMSERPINE1NR1H4TRPV1
SCHEMBL19512005 0.84 KDM4E (0.57) KDM4EPKMLTC4STRPV1DVL1
SCHEMBL19512111 0.80 KDM4E (0.49) KDM4EPKMLTC4STRPV1DVL1
SCHEMBL19512038 0.79 HCAR2 (0.53) KDM4EPKMSERPINE1NR1H4TRPV1
SCHEMBL19512025 0.79 KDM4E (0.44) KDM4ETRPV1NLRP3ALDH1A1KCNQ2
SCHEMBL14075292 0.77 KDM4E (0.62) KDM4EPKMLTC4SNLRP3DVL1
SCHEMBL19512124 0.76 ACLY (0.60) KDM4EPKMSERPINE1TRPV1ALDH1A1
SCHEMBL22080099 0.75 VNN1 (0.43) KDM4ETRPV1NLRP3ALDH1A1KCNQ2
SCHEMBL19512123 0.75 KDM4E (0.49) KDM4EPKMTRPV1ALDH1A1KCNQ2
SCHEMBL19512047 0.74 KDM4E (0.62) KDM4EPKMTRPV1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180037538-A1 DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2018-02-08 — — US claimed
EP-3239133-A1 DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2017-11-01 — — EP claimed
US-20180037538-A1 DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2018-02-08 — — US disclosed
EP-3239133-A1 DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2017-11-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180037538-A1 DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF NCS1, CACNA1B, ORAI1 KDM4E 659/4885PKM 974/4885SERPINE1 4494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback